- Home
- CTW vs MCRB Comparison
CTW vs MCRB Comparison
Compare CTW & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTW
- MCRB
- Stock Information
- Founded
- CTW 2013
- MCRB 2010
- Country
- CTW Japan
- MCRB United States
- Employees
- CTW N/A
- MCRB N/A
- Industry
- CTW EDP Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- CTW Technology
- MCRB Health Care
- Exchange
- CTW Nasdaq
- MCRB Nasdaq
- Market Cap
- CTW 171.4M
- MCRB 165.3M
- IPO Year
- CTW 2025
- MCRB 2015
- Fundamental
- Price
- CTW $1.93
- MCRB $18.80
- Analyst Decision
- CTW
- MCRB Hold
- Analyst Count
- CTW 0
- MCRB 4
- Target Price
- CTW N/A
- MCRB $73.67
- AVG Volume (30 Days)
- CTW 250.4K
- MCRB 118.7K
- Earning Date
- CTW 01-01-0001
- MCRB 08-06-2025
- Dividend Yield
- CTW N/A
- MCRB N/A
- EPS Growth
- CTW N/A
- MCRB N/A
- EPS
- CTW N/A
- MCRB 10.22
- Revenue
- CTW $76,194,020.00
- MCRB N/A
- Revenue This Year
- CTW N/A
- MCRB N/A
- Revenue Next Year
- CTW N/A
- MCRB N/A
- P/E Ratio
- CTW $47.65
- MCRB $1.85
- Revenue Growth
- CTW 8.71
- MCRB N/A
- 52 Week Low
- CTW $1.71
- MCRB $6.53
- 52 Week High
- CTW $4.88
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- CTW N/A
- MCRB 61.47
- Support Level
- CTW N/A
- MCRB $18.43
- Resistance Level
- CTW N/A
- MCRB $19.87
- Average True Range (ATR)
- CTW 0.00
- MCRB 1.30
- MACD
- CTW 0.00
- MCRB -0.08
- Stochastic Oscillator
- CTW 0.00
- MCRB 62.71
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.